VITRASE
(Vitrase)Phase 3Protein / enzyme
VITRASE is one of 5 small molecule programs targeting Vitreous Hemorrhage. It is currently in Phase 3.
1
Indications
7
Total Trials
0
Active Trials
4
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Vitreous Hemorrhage
#DrugCompanyPhaseTrials
1Lucentis
RocheApproved
Eylea
RegeneronPhase 2
Avastin
BBio-Thera Solutions
Phase 2
VITRASE
BBausch & Lomb Incorporated
Phase 3
AMPHADASE
AAmphastar Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypersensitivity2 trials
Vitreous Hemorrhage2 trials
ESS1 trial
Absorption1 trial
Regulatory
FDA Approval Timeline[4]
May 5, 2004
VITRASE
BLA BLA021640
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vitrase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- BBausch & Lomb Incorporated